Updates are available Correction dated 2025-07-10

Documents that mention this clinical trial

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288

Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
https://doi.org/10.1136/esmoopen-2020-001110

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba5506

Neoadjuvant immunotherapy of locoregionally advanced solid tumors
https://doi.org/10.1136/jitc-2022-005036

Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study
https://doi.org/10.1136/ijgc-2019-000512

Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023
https://doi.org/10.1136/ijgc-2023-005132

#1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial
https://doi.org/10.1136/ijgc-2023-esgo.899

Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8⁺ TILs based on <i>BRCA1/2</i> mutation status in epithelial ovarian cancers
https://doi.org/10.1136/jitc-2024-009058

Treatment of epithelial ovarian cancer
https://doi.org/10.1136/bmj.m3773

Documents that mention this clinical trial

Advanced Clinical Trials of Dendritic Cell Vaccines in Ovarian Cancer
https://doi.org/10.1136/jim-2020-001355

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
https://doi.org/10.1136/esmoopen-2020-001110

Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study
https://doi.org/10.1136/ijgc-2019-000512

Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8⁺ TILs based on <i>BRCA1/2</i> mutation status in epithelial ovarian cancers
https://doi.org/10.1136/jitc-2024-009058

Documents that mention this clinical trial

Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
https://doi.org/10.1136/esmoopen-2020-001110

Neoadjuvant immunotherapy of locoregionally advanced solid tumors
https://doi.org/10.1136/jitc-2022-005036

Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8⁺ TILs based on <i>BRCA1/2</i> mutation status in epithelial ovarian cancers
https://doi.org/10.1136/jitc-2024-009058

Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
https://doi.org/10.1136/ijgc-2021-002593

Documents that mention this clinical trial

Advanced Clinical Trials of Dendritic Cell Vaccines in Ovarian Cancer
https://doi.org/10.1136/jim-2020-001355

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288

P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC)
https://doi.org/10.1136/ijgc-2019-esgo.179

Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499

Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
https://doi.org/10.1136/esmoopen-2020-001110

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
https://doi.org/10.1136/ijgc-2021-002933

Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative
https://doi.org/10.1136/ijgc-2022-004160

Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.
https://doi.org/10.1200/jco.2024.42.16_suppl.5554

176 Rucaparib maintenance treatment in patients (Pts) with newly diagnosed ovarian cancer (OC): defining benefit according to disease risk subgroups within the phase 3 ATHENA-MONO study
https://doi.org/10.1136/ijgc-2024-esgo.584

2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246)
https://doi.org/10.1136/ijgc-2022-esgo.1018

Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8⁺ TILs based on <i>BRCA1/2</i> mutation status in epithelial ovarian cancers
https://doi.org/10.1136/jitc-2024-009058

New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580

O026/#560 Efficacy analysis by disease risk subgroup for the phase 3 athena-mono study (GOG-3020/engot-OV45) evaluating rucaparib maintenance treatment in patients with newly diagnosed ovarian cancer
https://doi.org/10.1136/ijgc-2022-igcs.28

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
https://doi.org/10.1200/jco.22.01003